Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"
We could not find results for this trial
I know where the results areWhat it found
We found no results in the registry or in papers.
This trial finished 2 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Glatiramer acetate
Unknown
What it measured
Main measures
Percentage of participants who had one or more adverse events
Up to 24 months
SafetyAnnual Relapse Rate (ARR)
Up to 24 months
Relapses
Other measures (3)
Changes in the number of lesions from brain MRI findings
Up to 24 months
MRI lesionsChanges in functional evaluation scores (Expanded Disability Status Scale [EDSS])
Up to 24 months
Disability progressionChanges in functional evaluation scores (Functional Systems [FS])
Up to 24 months
VisionBladder, bowel and sexual function
Who could take part
MS (type not specified)
Inclusion Criteria: - All patients treated with Copaxone from the first day of market launch of the product Exclusion Criteria: -None
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
The purpose of this study is to evaluate the safety and efficacy of Copaxone subcutaneous injection syringe (hereinafter referred to as Copaxone) in patients with multiple sclerosis in the routine clinical setting.
Loading reviews and guidelines…
Related trials
- CPE
Completed
No result found
- TOP MS
Completed
Result in a paper, not read yet
- Long Term Safety of Teriflunomide When Added to Interfero…
Phase 2 · Completed
Main goal was not benefit
- Phase II Study of Teriflunomide as Adjunctive Therapy to …
Phase 2 · Completed
Main goal was not benefit
History
Started
Nov 2015
Main results due
Mar 2024
Finished
Mar 2024
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error